Lionel ADES
Hôpital Saint Louis · APHP · Groupe Francophone des Myelodysplasies
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lionel ADES as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:21 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05181735 · Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESAGroupe Francophone des Myelodysplasies · recruiting · MDS, Myelodysplastic Syndromes · principal investigator
- Ph2NCT03744390 · IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeGroupe Francophone des Myelodysplasies · active not recruiting · Myelodysplastic Syndromes, Leukemia Acute Myeloid · principal investigator
- Ph2NCT02335268 · Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and ThrombocytopeniaGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH · completed · Myelodysplastic Syndromes · study director
- Ph2NCT02197676 · A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseGroupe Francophone des Myelodysplasies · completed · MDS · principal investigator
- Ph1/Ph2NCT01305135 · Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic SyndromesGroupe Francophone des Myelodysplasies · completed · High Grade Myelodysplastic Syndrome Lesions · principal investigator
- Ph2NCT01088373 · Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5qGroupe Francophone des Myelodysplasies · completed · Myelodysplastic Syndromes · principal investigator
- Ph1/Ph2NCT01085838 · Erlotinib in Higher Risk Myelodysplastic SyndromeGroupe Francophone des Myelodysplasies · completed · Myelodysplastic Syndrome · principal investigator
- Ph2NCT00437450 · Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic AcidGroupe Francophone des Myelodysplasies · unknown · Anemia in Myelodysplastic Syndromes · principal investigator
- Ph3NCT00378365 · Acute Promyelocytic Leukemia 2006 (APL)Assistance Publique - Hôpitaux de Paris · unknown · Leukemia, Promyelocytic, Acute · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:21 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.N Engl J Med · 2020459 citationsRCR 20.6
- 332 citationsRCR 8.7
- Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.Clin Infect Dis · 2009306 citationsRCR 10.5
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).J Clin Oncol · 2021263 citationsRCR 13.3
- 262 citationsRCR 6.3
- Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.Blood · 2015225 citationsRCR 6.7
- 200 citationsRCR 5.0
- Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.Leukemia · 2021178 citationsRCR 8.8
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Blood · 2011173 citationsRCR 3.9
- Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.J Clin Oncol · 2006128 citationsRCR 2.8